BioSpace News Archive

Global life sciences leader selects Vault Study Startup and Vault eTMF to improve trial efficiency

Physicians in First Coast jurisdictions may now seek professional payment for insertion of DEXTENZA® using CPT code 0356T

Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties

Nemaura Medical, Inc., a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor, announced that it has commissioned the integration of data from third party wearable devices into its proBEAT™ app which is planned for launch in the USA later this year.

- Jakafi® demonstrated superior overall response rate in patients with steroid-refractory chronic graft-versus-host disease at Week 24 compared to best available therapy

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-24

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on July 30, 2020 at 4:30 p.m. ET to review its second quarter 2020 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity’s website at www.infi.com . To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-45

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC Re-initiating clinical development focusing first on Phase 3 for PBC

Astellas & Golden Ticket; sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

Beckman Coulter today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its PK7400 Automated Microplate System and the system’s reagents have completed FDA approval.